The 35th ESMO Congress, Milan 2010
2010年10月8日〜12日にイタリア・ミラノにて開催されたthe 35th ESMO Congressよ
り、大腸癌と胃癌の注目演題のレポートをお届けします。演題レポートの冒頭には、
臨床研究の第一線で活躍する監修ドクターのコメントを掲載しています。
2010年11月9日 演題レポート#LBA19/580O、#709PDを更新しました。
2010年11月1日 サイトをアップしました。
Cediranib plus FOLFOX/XELOX versus placebo plus FOLFOX/XELOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, Phase III study (HORIZON II)
P.M. Hoff, et al.
mFOLFOX6 + cediranib versus mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer: a randomized, double-blind, Phase II/III study (HORIZON III)
H-J. Schmoll, et al.
|
Efficacy and safety of second-line treatment with panitumumab plus irinotecan, both given every three weeks (Q3W), in patients (pts) with
wild-type (WT) K-RAS metastatic colorectal cancer (mCRC): A study from the Spanish Cooperative Group for the Treatment of Digestive tumours
(TTD)
A. Gomez, et al.
|
Five-year results of the randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients after curative D2 gastrectomy (ACTS-GC study)
M. Sasako, et al.
|
Randomized, double-blind, placebo-controlled, multicentre phase III study of Capecitabine / Cisplatin + Bevacizumab or placebo as 1st-line
therapy in patients with advanced gastric cancer (AVAGAST update)
E. van Cutsem, et al.
Tumour biomarker analyses in the AVAGAST phase III randomized study of first-line Bevacizumab + Capecitabine/Cisplatin in patients with advanced gastric cancer
M.A. Shah, et al.
|
|
KRAS mutational status in Japanese patients with colorectal cancer: Results from a multicenter, cross-sectional, large observational study conducted by the Japan Study Group of KRAS Mutation in Colorectal Cancer
K. Yamazaki, et al.
|
|
Multicenter Phase II study of second-line FOLFIRI + Cetuximab with KRAS wild type gene in metastatic CRC (FLIER)
T. Kato, et al.
|
|
Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab in Patients with Metastatic Colorectal Cancer
Y. Komatsu, et al.
|
|
Phase II Study of First-line Sunitinib in Combination with Irinotecan, Leucovorin, and 5-fluorouracil (FOLFIRI) in Japanese
Patients with Unresectable/Metastatic Colorectal Cancer
A. Tsuji, et al.
|
Phase II Study with Panitumumab, Oxaliplatin, 5-fluorouracil and Concurrent Radiotherapy in High-risk Locally Advanced Rectal Cancer Patients (STARPAN/STAR-02 Study), Final Results
C. Pinto, et al.
|
 |
 |
